Welcome to visit Zhongnan Medical Journal Press Series journal website!

Home Articles Vol 32,2023 No.12 Detail

Severe bradycardia caused by the combined use of voriconazole and ivabradine

Published on Nov. 02, 2023Total Views: 781 times Total Downloads: 270 times Download Mobile

Author: Bei-Hua LI 1 Yan WANG 2 Hai-Tao WANG 2

Affiliation: 1. Department of Pharmacy, Shaanxi Traffic Hospital, Xi’an 710000, China 2. Department of Pharmacy, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China

Keywords: Voriconazole Ivabradine Bradycardia Drug interaction Adverse drug reactions

DOI: 10.19960/j.issn.1005-0698.202312015

Reference: Bei-Hua LI, Yan WANG, Hai-Tao WANG.Severe bradycardia caused by the combined use of voriconazole and ivabradine[J].Yaowu Liuxingbingxue Zazhi,2023, 32(12):1316-1440.DOI: 10.19960/j.issn.1005-0698.202312015.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

A 15-year-old female patient with lupus nephritis and heart failure, who had been on long-term treatment with metoprolol and ivabradine, maintained a heart rate of 65-70 beats per minute after admission. On the 14th day of admission, the patient developed a pulmonary aspergillus infection, and after 3 days of adding voriconazole antifungal treatment, the patient experienced severe bradycardia, with her heart rate dropping to 45 beats per minute. The clinical pharmacist, in combination with the patient's combined medication history and pharmacokinetic characteristics, used Naranjo's assessment scale and DIPS score to determine that the adverse reaction was due to the drug interaction between voriconazole and ivabradine, and suggested to continue voriconazole antifungal treatment and discontinue ivabradine. The doctor accepted this suggestion, and the patient's heart rate returned to 65 beats per minute the next day. The clinical pharmacist timely identified and intervened in the adverse reaction induced by the drug interactions, which promoted rational clinical medication and ensured the patient's medication safety.

Full-text
Please download the PDF version to read the full text: download
References

1.Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4): e1-e60. DOI: 10.1093/cid/ciw326.

2.李博, 高蕊, 李睿, 等. 药物临床试验不良反应/不良事件关联性判定方法研究探讨[J]. 中国新药杂志, 2014, 23(12): 1465-1470. [Li B, Gao R, Li R, et al. Study on the method of adverse reaction/adverse event correlation in drug clinical trial[J]. Chinese Journal of New Drugs, 2014, 23(12): 1465-1470.] DOI: CNKI:SUN:ZXYZ.0. 2014-12-026.

3.潘莹,魏雪,刘韬,等.基于药物相互作用可能性量表客观评价临床药物相互作用[J]. 今日药学, 2012, 22(3): 148-150, 155. [Pan Y, Wei X, Liu T, et al. Objective evaluation of clinical drug interaction based on drug interaction possibility scale[J]. Pharmacy Today, 2012, 22(3): 148-150, 155.] DOI: CNKI:SUN:YAXU.0.2012-03-011.

4.Kamisah Y, Che Hassan HH. Therapeutic use and molecular aspects of ivabradine in cardiac remodeling: a review[J]. Int J Mol Sci, 2023, 24(3): 2801. DOI: 10.3390/ijms24032801.

5.Zhou JM, Xu YM, Zhang YH, et al. Real-world effectiveness of ivabradine in Chinese patients with chronic heart failure: interim analysis of the POSITIVE study[J]. Am J Cardiovasc Drugs, 2022, 22(3): 345-354. DOI: 10.1007/s40256-021-00500-x.

6.胡大一, 黄德嘉, 袁祖贻, 等. 盐酸伊伐布雷定治疗中国慢性心力衰竭患者的有效性及安全性评价: SHIFT研究中国亚组数据分析[J]. 中华心血管病杂志, 2017, 45(3): 190-197. [Hu DY, Huang DJ, Yuan ZY, et al. Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study[J]. Chinese Journal of Cardiology, 2017, 45(3): 190-197.] DOI: 10.3760/cma. j. issn.0253-3758.2017.03.005.

7.Chen C, Kaur G, Mehta PK, et al. Ivabradine in Cardiovascular disease management revisited: a review[J]. Cardiovasc Drugs Ther, 2021, 35(5): 1045-1056. DOI: 10.1007/s10557-020-07124-4.

8.Vlase L, Popa A, Neag M, et al. Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects[J]. Clin Drug Investig, 2012, 32(8): 533-538. DOI: 10.1007/BF03261904.

9.Cocco G, Jerie P. Torsades de pointes induced by the concomitant use of ivabradine and  azithromycin: an unexpected dangerous interaction[J]. Cardiovasc Toxicol, 2015, 15(1): 104-106. DOI: 10.1007/s12012-014-9274-y.

10.王琴琴, 黄崇媚, 罗环, 等. 环孢素致罕见脑病1例[J]. 药物流行病学杂志, 2021, 30(6): 422-424.[Wang QQ, Huang CM, Luo H, et al. Rare encephalopathy due to cyclosporine a case[J]. Chinese Journal of Pharmacoepidemiology, 2021, 30(6): 422-424.] DOI: 10.19960/j.cnki.issn1005-0698.2021.06.013.

11.邬丽玲, 陈超, 李晓红, 等. 1例伏立康唑片引起他克莫司血药浓度升高的病例分析[J]. 海峡药学, 2023, 35(1): 69-72. [Wu LL, Chen C, Li XH, et al. An analysis of a case with increased serum tacrolimus concentration caused by voriconazole tablets[J]. Strait Pharmaceutical Journal, 2023, 35(1): 69-72.] DOI: 10.3969/j.issn.1006-3765.2023.01.016.

12.陈凡, 胡松. 伊伐布雷定联合伏立康唑致视物模糊和头昏1例[J]. 中国医院药学杂志, 2020, 40(11): 1285-1286. [Chen F, Hu S. Ivabradine combined with voriconazole causes blurred vision and dizziness: 1 case[J].Chinese Journal of Hospital Pharmacy, 2020, 40(11): 1285-1286.] DOI: 10.13286/j.1001-5213.2020.11.24.

13.Singh K, Alagarraju MR, Wolf CE, et al. Ivabradine toxicity: a case report[J]. J Med Case Rep, 2022, 16(1): 392. DOI: 10.1186/s13256-022-03554-w.

14.中华医学会呼吸病学分会感染学组, 中华结核和呼吸杂志编辑委员会. 肺真菌病诊断和治疗专家共识[J]. 中华结核和呼吸杂志, 2007, 30(11): 821-834. DOI: 10.3760/j.issn:1001-0939.2007.11.008.

15.Nusair MB, Al-Azzam SI, Arabyat RM, et al. The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan[J]. Saudi Pharm J, 2020, 28(2): 155-160. DOI: 10.1016/j.jsps.2019.11.009.

Popular papers
Last 6 months